drugset / Trial / NCT02905981
Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol
Non-randomizedCrossoverOpen-labelTreatment
Summary
The main purpose is to determine whether Triferic, administered orally with Shohl's solution, is safe and effective for the treatment of iron-refractory iron-deficiency anemia (IRIDA).
Timeline
- Start
- 2017-01-17
- Primary completion
- 2018-03-15
- Completion
- 2018-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ferrous Sulfate | Diagnostic / imaging agent | 3 mg/kg | Oral |
| Subject | Triferic | Other / unclassified | 3 mg/kg | Oral |
| Background | Shohl's solution | Unknown | 0.67 mmol | Oral |